Bioventrix to Highlight Novel Transcatheter Approach for Heart Failure Treatment at EuroPCR Congress
SAN RAMON, Calif., and PARIS, May 19, 2014 — BioVentrix, a pioneer of technologies and products for less invasive treatment of heart failure (HF), today announced that early clinical experience from its next generation device, the Revivent-TC™ Ventricular Enhancement System, which uses a hybrid transcatheter approach, will be the focus of a satellite symposium at the prestigious 2014 EuroPCR Congress as well as three other scientific presentations. Additional presentations will detail ongoing results with the Company’s flagship product, the Revivent™ Myocardial Anchoring System.
Prof. Horst Sievert from the CardioVascular Center (Frankfurt, Germany) will chair the symposium, entitled “Transcatheter Treatment of Ischaemic Heart Failure: The Less Invasive Ventricular Enhancement™ (LIVE™) Procedure Using the Revivent Myocardial Anchoring System.” Scheduled for 21 May 2014 from 12:30-13:30 in Room 353, symposia faculty and their presentations will include:
- Prof. Olaf Wendler, King’s College Hospital (London, UK): “The LIVE procedure: Technology and Techniques.”
- Prof. Helge Moellmann, Kerckhoff-Klinik (Bad Nauheim, Germany): “Revivent and Revivent-TC: Clinical results to date.”
- Prof. Petr Neuzil, Na Homolce Hospital (Prague, Czech Republic): “Clinical case reports and identifying the ideal patient candidate for the LIVE procedure.
To register for the symposium and to hear a two-minute preview from Prof. Sievert and other faculty please click here.
“We are very pleased with our early experience using the transcatheter hybrid procedure,” said Petr Neuzil, MD, PhD, Head of Cardiology and Director of the Cardiac Arrhythmia Service at Na Homolce Hospital. “The Revivent and Revivent-TC systems provide life-saving treatment in critically ill patients for whom there are few other options. Many key opinion leaders have enthusiastically embraced the new transcatheter approach, which expands the LIVE procedure for use on heart failure patients that cannot withstand the stress of a standard, on-pump, open surgical procedure.”
The complete schedule of scientific presentations highlighting BioVentrix technology and the LIVE procedure includes:
Tuesday, 20 May 2014, 15:20–16:50, Room Maillot
Session: Cardiovascular Innovation Pipeline-New Devices for Coronary Artery Disease and Heart Failure
Hybrid transcatheter therapy for ischaemic cardiomyopathy heart failure
Lon Annest, MD
Wednesday, 21 May 2014, 10:30 –12:00
Interactive Case Corner 07 (Ref. Euro14A–POS186)
Closed chest, transcatheter LV volume reduction for ischaemic cardiomyopathy
Lon Annest, MD
Thursday, 22 May 2014, 14:40–16:40, Theatre Havane
Session: Device-based LV cavity reshaping in heart failure
Case-based Less Invasive Ventricular Enhancement (LIVE) presentation
G. Davidavicius, MD
Poster Sessions: Displayed from 20–23 May 2014
Poster Euro14A-POS186-Zone C-Level 3
Thoracoscopically Assisted Transcatheter Ventricular Restoration: a Novel Therapy for Ischemic HF with Anteropical Aneurysmal in Ovine Model
Mr. Yanping Cheng
Poster Euro14A-POS226-Zone D-Level 3
Early Results of Less Invasive Ventricular Enhancement (LIVE) procedure for LV Volume Reduction in Ischemic Cardiomyopathy Patients
Prof. Olaf Wendler
About the Revivent System and the LIVE Procedure
Placement of the Revivent System via the LIVE procedure obviates the need for more invasive surgery. Instead, small titanium anchors are placed along the outer surface of the heart and along one of the interior walls via a catheter-based approach. The anchors are then pulled toward one another, effectively excluding the scarred, and non-functioning heart wall. The efficiency of the remaining heart muscle is immediately improved, by as much as 30-40 percent, according to data presented at the 2013 European CardioThoracic Society Annual meeting.
NOTE: The Revivent Myocardial Anchoring System is approved for sale in Europe; it is not approved for sale in the United States. The Revivent-TC Ventricular Enhancement System requires regulatory approval and is not yet commercially available.
Contact: David Schickling, VP of Sales and Marketing, +1-925-830-1000.